Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

DISCONTINUED OPERATIONS AND DECONSOLIDATION OF TRICHOME (Tables)

v3.24.1
DISCONTINUED OPERATIONS AND DECONSOLIDATION OF TRICHOME (Tables)
12 Months Ended
Dec. 31, 2023
Discontinued Operations And Deconsolidation [Abstract]  
Disclosure of consolidated statement of financial position of discontinued operations [Table Text Block]
 
   
November 6,
2022
   
December 31,
2021
 
ASSETS
           
             
CURRENT ASSETS:
           
Cash and cash equivalents
 
$
406
   
$
3,171
 
Trade receivables
   
1,047
     
8,486
 
Other accounts receivable
   
2,194
     
11,198
 
Loans receivable
   
1,010
     
2,708
 
Biological assets
   
444
     
1,435
 
Inventories
   
6,784
     
9,715
 
                 
     
11,885
     
36,713
 
NON-CURRENT ASSETS:
               
Property, plant and equipment, net
   
14,645
     
21,236
 
Derivative assets
   
-
     
14
 
Right-of-use assets, net
   
10,999
     
14,570
 
Intangible assets, net
   
17,157
     
22,846
 
Goodwill
   
-
     
107,854
 
                 
     
42,801
     
166,520
 
                 
Total assets
 
$
54,686
   
$
203,233
 
                 
LIABILITIES
               
                 
CURRENT LIABILITIES:
               
Trade payables
 
$
7,266
   
$
4,667
 
Bank loans and credit facilities
   
3,774
     
8,684
 
Other accounts payable and accrued expenses
   
25,217
     
14,019
 
Current maturities of operating lease liabilities
   
869
     
841
 
                 
     
37,126
     
28,211
 
NON-CURRENT LIABILITIES:
               
Operating lease liabilities
   
13,517
     
14,883
 
Deferred tax liability, net
   
2,872
     
4,065
 
                 
     
16,389
     
18,948
 
                 
Total liabilities
 
$
53,515
   
$
47,159
 
Disclosure of analysis of single amount of discontinued operations [Table Text Block]
   
Period ended
November 6,
2022
   
Year ended
December 31,
2021
 
             
Revenues
 
$
28,171
   
$
20,247
 
Cost of revenues
   
24,227
     
16,960
 
                 
Gross profit before fair value adjustments
   
3,944
     
3,287
 
                 
Fair value adjustments:
               
Unrealized change in fair value of biological assets
   
399
     
902
 
Realized fair value adjustments on inventory sold in the period
   
(2,528
)
   
(226
)
                 
Total fair value adjustments
   
(2,129
)
   
676
 
                 
Gross profit
   
1,815
     
3,963
 
                 
General and administrative expenses
   
38,464
     
14,998
 
Impairment of goodwill, intangible assets, right-of-use assets and fixed assets
   
115,112
     
-
 
Selling and marketing expenses
   
4,912
     
2,270
 
Restructuring expenses
   
4,506
     
-
 
Share-based compensation
   
1,130
     
2,049
 
                 
Total operating expenses
   
164,124
     
19,317
 
                 
Operating loss
   
(162,309
)
   
(15,354
)
                 
Finance expenses, net
   
(5,264
)
   
(2,495
)
                 
Loss before income taxes
   
(167,573
)
   
(17,849
)
Income tax expense (benefit)
   
(1,194
)
   
5
 
                 
Net loss from discontinued operations, net of tax
 
$
(166,379
)
 
$
(17,854
)
Disclosure of net cash flows provided by (used in) the discontinued operations [Table Text Block]
 
   
Period ended
November 6,
2022
   
Year ended
December 31,
2021
 
             
Operating activities
 
$
(300
)
 
$
(10,621
)
                 
Investing activities
 
$
(615
)
 
$
(1,434
)
                 
Financing activities
 
$
(1,850
)
 
$
14,864
 
 
  *)
From business combination dated, March 18, 2021.